Back to Search Start Over

Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences.

Developing strategies to link basic cardiovascular sciences with clinical drug development: another opportunity for translational sciences.

Authors :
Feldman AM
Koch WJ
Force TL
Source :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2007 Jun; Vol. 81 (6), pp. 887-92. Date of Electronic Publication: 2007 Mar 28.
Publication Year :
2007

Abstract

Driven, at least in part, by the National Institutes of Health roadmap, an increasing number of studies has bridged the chasm between observations in the basic research laboratory and the clinical bedside. These studies have been an integral part in "translating" new discoveries into therapeutic initiatives. However, "translational medicine" has been used less frequently in the development of cardiovascular drugs or in predicting the potential cardiovascular toxicity of non-cardiac agents. Studies in animal models can provide important clues as to the potential cardiotoxicity of new therapeutic agents, as well as providing a template for the rational design of clinical trials. Three examples of drug development programs that might have been altered by clues available from laboratory studies include the development programs for the anti-cancer drug trastuzumab, the cyclooxygenase inhibitors, and the adenosine-receptor agonists and antagonists. Although mouse models may not always represent the physiology of humans, they provide important information that clinical scientists can utilize in designing safe programs for the evaluation of new pharmacologic agents.

Details

Language :
English
ISSN :
0009-9236
Volume :
81
Issue :
6
Database :
MEDLINE
Journal :
Clinical pharmacology and therapeutics
Publication Type :
Academic Journal
Accession number :
17392727
Full Text :
https://doi.org/10.1038/sj.clpt.6100160